News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II (World)
Boehringer Ingelheim Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn’s Disease 5/24/2016
Isofol Medical AB Announces Successful Meetings With European And US Regulatory Authorities Regarding The Design Of A Pivotal Phase II Clinical Trial Of Isofol's Lead Drug Candidate, Modufolin 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
DS Biopharma Announces DS102 Will Be Developed For Pulmonary Disorders In Addition To NASH 5/23/2016
ViroMed Of Korea Receives U.S. Fast Track Status For Gene Therapy 5/20/2016
NovoCure Enrolls Last Patient In INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel In Recurrent Ovarian Cancer 5/20/2016
ProNAi Therapeutics, Inc. To Report Wolverine Phase 2 Interim Results On June 6th At ASCO 5/19/2016
Bone Therapeutics To Enhance Value Of Its Severe Osteoporosis Program By Transitioning To Allogeneic Development 5/19/2016
BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences 5/19/2016
NovoCure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients 5/19/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Preliminary Data From Randomized Phase II Study Of REOLYSIN In Non-Small Cell Lung Cancer 5/19/2016
Health Canada Authorizes ProMetic Life Sci (PFSCF.PK) To Proceed With Its PBI-4050 Clinical Trial In Patients With Cystic Fibrosis 5/18/2016
Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 5/18/2016
Sophiris Bio (SPHS) Reports First Quarter 2016 Financial Results And Key Business Highlights 5/17/2016
BioLineRx Reports First Quarter 2016 Financial Results 5/17/2016
Bone Therapeutics Announces Further Positive Efficacy In ALLOB Phase I/IIA Delayed-Union Fracture Trial 5/17/2016
Theranexus Reaches Its Primary Endpoint In The Proof Of Concept Trial Of THN102 In Excessive Daytime Sleepiness (EDS) 5/17/2016
Hansa Medical: Ongoing US Study Shows That IdeS Allows For Transplantation Of Highly Sensitized Patients 5/17/2016
Allergan (AGN) Shows Off Positive Mid-Stage Data for Oculeve Intranasal Tear Neurostimulator 5/16/2016
BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia 5/16/2016
BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement 5/16/2016
Mundipharma And Purdue Pharma L.P. Expand Pain Pipeline With New Deal For First-In-Class Sigma-1 Antagonist (S1A Or MR309/E-52862) From ESTEVE 5/16/2016
BioNevia And Neuromax Announce Completion Of Enrollment In Phase IIb Clinical Trial Of BNV-222 5/16/2016
PledPharma Release: New Data Strengthens Claim That Pledox Does Not Negatively Interfere With The Anti-Cancer Effect Of Chemotherapy 5/16/2016
Transition Therapeutics (TTH.TO) Announces Third Quarter Fiscal 2016 Financial Results 5/12/2016
Helix Release: First Patient Dosed In Phase II Study Of L-DOS47 In Non-Small Cell Lung Cancer 5/12/2016
Braeburn Pharma, Camurus Announce Positive Mid-Stage CAM2038 Data in Patients With Opioid Use Disorder 5/11/2016
Medivir (MVRBF) Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C 5/11/2016
ProNAi Therapeutics, Inc. Reports First Quarter 2016 Results 5/10/2016
BrainStorm Cell Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
BioLineRx To Report First Quarter 2016 Results On May 17, 2016 5/10/2016
Verona Pharma (VRP.L) Announces Positive Results From "Add-On" Phase II Trial With RPL554 5/10/2016
Allergy Therapeutics plc Race with Positive Phase II Data for Hayfever 5/9/2016
Galmed Pharmaceuticals First Quarter 2016 Conference Call And Webcast Scheduled For Monday, May 16th, 2016 5/9/2016
Aurinia (ISA.TO) Initiates First Clinical Study Of Voclosporin For Japan 5/9/2016
NeuroDerm (NDRM) Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson’s Disease 5/9/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 First Quarter Results 5/6/2016
Novaliq GmbH Announces Last Patient Enrolled In Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease 5/5/2016
Opthea Doses First Patient In Phase 2A Dose Expansion Study For OPT-302 In Wet AMD 5/5/2016
SELLAS Life Sciences Group Announces Positive WT1 Cancer Vaccine (Galinpepimut-S) Clinical Results At The 13th International Conference Of The International Mesothelioma Interest Group (iMig) 5/4/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
Mount Sinai And Galmed Pharmaceuticals To Collaborate In An Investigator Initiated Phase Ila Trial To Evaluate The Effect Of AramcholTM In Combination With Vitamin D For The Treatment Of Patients With Fibrotic Nonalcoholic Fatty Liver Disease 5/3/2016
Foamix Pharma (FOMX) Announces Completion Of Enrollment In Phase II Clinical Trial Of Minocycline Foam (FMX103) For Treatment Of Papulopustular Rosacea 5/3/2016
Bone Therapeutics Completes Recruitment Of Its ALLOB Phase IIA Spinal Fusion Study 5/3/2016
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
BioInvent (BOVNF), Oncurious And NMTRC Initiating Phase I/IIa Study With TB-403 For The Treatment Of Medulloblastoma 5/2/2016
Glycotope Appoints Dr. Alfredo Zurlo As Chief Medical Officer 4/29/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Neovacs Obtains FDA Approval To Extend Its Phase IIb Clinical Trial In Lupus To United States 4/29/2016
Anavex (AVXL)’s Alzheimer’s Drug a Possible Game Changer After Patients Reported Remarkable Positive Response 4/28/2016
Neovacs Obtains FDA Approval To Extend Its Phase IIb Clinical Trial In Lupus To United States 4/28/2016
Life Science Startup Company Strekin AG Announces The Launch Of A Phase 2 Clinical Study Of STR001 As A Potential New Treatment For Hearing Loss 4/27/2016
ABIVAX Abstract On ABX464 Selected For Presentation At The AIDS 2016 Conference In Durban, South Africa 4/27/2016
Transition Therapeutics (TTH.TO) Announces Dosing Of First Patient In Phase 2 Study Of Drug Candidate TT701 4/26/2016
Novartis AG (NVS)'s Breakthrough Muscle Drug Fails to Meet Primary Goal in Patients with sIBM 4/21/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/20/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
AbbVie (ABBV)'s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial 4/18/2016
MorphoSys AG Licensing Partner GlaxoSmithKline (GSK) Starts Phase 2 Study With GSK3196165 (MOR103) In Hand Osteoarthritis 4/18/2016
Pharma Mar Will Be Present At The 2016 Annual AACR Congress With The Latest Novelties In Its Compounds Of Marine Origin In Solid And Hematological Tumors 4/14/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
ORYZON Genomics Release: Data On ORY-1001 To Be Presented At The AACR Annual Meeting 2016 In New Orleans 4/11/2016
Debiopharm To Present The Latest Findings On Debio 1450 At ECCMID 4/8/2016
Galapagos (GLPG.BR) Initiates A Phase IIa Study With GLPG1690 In Idiopathic Pulmonary Fibrosis Patients 4/7/2016
Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters 4/7/2016
SanBio, Inc. Release: Clinical Trial Involving Regenerative Cell Treatment For Patients With Traumatic Brain Injury Permitted In Japan 4/6/2016
Kamada Ltd. (KMDA) Announces Initiation Of Phase 2 Clinical Trial With Intravenous Alpha-1 Antitrypsin For The Prevention Of Lung Transplant Rejection 4/6/2016
Oramed (ORMP) Completes Phase IIb Oral Insulin Study 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
RedHill Biopharma (RDHL) Announces Interim Results From Phase IIa Proof-Of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis 4/5/2016
Newron Pharma (NWRN) Release: Ongoing Phase II Study Of Evenamide (NW-3509) May Suggest An Alternative Approach To The Treatment Of Schizophrenia 4/5/2016
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On April 4-6, 2016 In Stockholm, Sweden 4/4/2016
Kiadis Pharma Presents Positive Data On The Primary Endpoint Of Its Single Dose Phase II Trial With ATIR101 4/4/2016
SELLAS Life Sciences To Present Phase II Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting And The <>13th International Conference Of The International Mesothelioma Interest Group (IMig) 4/1/2016
Senhwa Biosciences Release: FDA Approves Clinical Trial Application (CTA) For Phase I/II Clinical Trial Of CX-5461 In Solid Tumors And Breast Cancers 4/1/2016
GENFIT (ALGFT) To Begin Elafibranor Clinical Program In PBC 3/31/2016
Janssen To Unveil New Hepatitis B And C Data At The International Liver Congress 2016 Of The European Association For The Study Of The Liver (EASL) 3/30/2016
BioLineRx Ltd. Reports Successful Top-Line Results In Phase 2 Trial For AML 3/29/2016
Aurinia (ISA.TO) Announces Result From Data And Safety Monitoring Board For Its Phase 2b Study In Lupus Nephritis -- Study To Continue As Planned 3/29/2016
Living Cell Tech Starts Phase IIb Clinical Trial Of NTCELL For Parkinson’s Disease 3/24/2016
BioLineRx Ltd. Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment 3/23/2016
Newron Pharmaceuticals (NWRN) Release: Evenamide (NW-3509): Evidence Of Anti-Psychotic Efficacy As An Add-On To Antipsychotics In Ongoing Phase 2 Study May Suggest An Alternative Approach To The Treatment Of Schizophrenia 3/23/2016
ProMetic Life Sci (PFSCF.PK) Confirms PBI-4050's Positive Effects On Novel Biomarkers In Patients Suffering From Metabolic Syndrome And Type 2 Diabetes 3/22/2016
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Phase 2b Clinical Trial Of Myrcludex B 3/22/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
XTL Biopharma (XTLB) Completes Phase 2 Trial Design For Lead Compound hCDR1 In The Treatment Of Lupus 3/21/2016
Aurinia (ISA.TO) Reports Fourth Quarter And Full Year 2015 Financial Results And Recent Operational Highlights 3/21/2016
Isofol Medical AB Share Issue Oversubscribed, Securing Over SEK 39 Million To Strengthen The Ongoing Phase II Clinical Development Program Of Modufolin 3/17/2016
Galapagos (GLPG.BR) Doses First CF Patient With G551D Mutation In SAPHIRA 1 Study 3/17/2016
Enceladus Announces Positive Results From A Phase IIa Study In Patients With Active Ulcerative Colitis With Nanocort 3/16/2016
Publication In Retrovirology Of The Results Of Biosantech's Phase IIA Clinical Trial For The Anti-HIV Candidate Vaccine 3/16/2016
Asieris Pharma Announces Positive Data From Bladder Cancer Drug Trial 3/15/2016
Heart Metabolics Limited Announces Multiple Senior Appointments To Management Team 3/15/2016
Galmed Pharmaceuticals Fourth Quarter 2015 Conference Call And Webcast Scheduled For Tuesday, March 22nd, 2016 3/15/2016
DelMar Pharma Release: FDA Grants Second Orphan Designation For VAL-083 3/15/2016
Sylentis Reports Positive Phase II Results With SYL1001 In Treating Ocular Pain Related To Dry Eye Syndrome 3/14/2016
Investors Hold Their Breath for Data from Aduro Biotech (ADRO), Novartis AG (NVS) 3/11/2016
OncoGenex (OGXI) Reports Financial Results for Year End 2015 3/10/2016
BrainStorm Cell Announces Financial Results For 2015 And Provides Business Update 3/10/2016
Sound Pharmaceuticals, Inc. And University of Oxford Collaborate On A New Treatment For Bipolar Disorder 3/9/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs 3/8/2016
TRANSGENE (ENX:TNG) Reports 2015 Financial Results And Provides Outlook For 2016 3/8/2016
Nuvo Pharmaceuticals Inc. Announces Results From European Ankle Sprain Study With Pennsaid® 2% 3/7/2016
Otto von Guericke Universität Magdeburg Release: Major Liver Cancer Study Completes Palliative Cohort Enrolment 3/7/2016
Galmed Pharmaceuticals To Present At The ROTH Conference 3/7/2016
Chugai Pharma Announces Phase II Global Study Results Of Nemolizumab (CIM331) In Late-Breaking Research Forums At AAD 3/7/2016
Antibe Therapeutics (ATE.V)’ ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients 3/7/2016
iX Biopharma Reports Positive Results From Multi-Dose Waferminetm Clinical Trial 3/7/2016
Positive Early Stage Pompe Data Allows Sanofi Genzyme (SNY) to Begin Phase III Trial this Summer 3/4/2016
Protalix Biotherapeutics, Inc. (PLX) Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual Worldsymposium 2016 3/3/2016
ProNAi Therapeutics, Inc. Reports 2015 Year-End Financial and Operational Results 3/3/2016
Prima Biomed (PRR.AX) And WuXi Biologics Announce First Dose Of Chinese-Manufactured Biologic In EU Clinical Trial 3/2/2016
XTL Biopharma (XTLB) Expands Global IP Portfolio With Issued Patent In Hungary For Lupus Drug Hcdr1 3/2/2016
Aurinia (ISA.TO) To Present At The 36th Annual Cowan Health Care Conference 3/1/2016
Newron Pharmaceuticals (NWRN) Reports 2015 Financial Results 3/1/2016
Galmed Pharmaceuticals Announces The Enrollment Of The First Patient In The ARRIVE Study 3/1/2016
AstraZeneca PLC (AZN)'s Closely-Watched Mesothelioma Drug Fails Mid-Stage Study 2/29/2016
Clementia Announces Last Patient Enrolled In Phase 2 Trial Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 2/29/2016
SELLAS Life Sciences Announces FDA Orphan Drug Designation For WT1 Cancer Vaccine In Patients With Malignant Pleural Mesothelioma 2/29/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal 2/26/2016
ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir 2/25/2016
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) And UAB Expand Their Research To Two New Gene Therapies For Sanfilippo B Syndrome And Hunter Syndrome 2/25/2016
Avraham Pharmaceuticals Ltd. Closes An Additional Investment Round Of Approximately $4.0 Million 2/25/2016
Mauna Kea Technologies Completes Enrollment Of 200 Patient Contact II Study On Characterization Of Pancreatic Cysts With Needle-Based Confocal Laser Endomicroscopy 2/25/2016
ViiV Healthcare Announces Phase II Study Results For First Two Drug, Long-Acting Injectable Regimen For HIV-1 Treatment 2/24/2016
Janssen Sciences Ireland UC Release: First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented At CROI 2/24/2016
PharmaEssentia Announces Phase II Results Of P1101, An Innovative, Mono-Pegylated Interferon In Patients With Chronic HCV Genotype 1 Infection 2/23/2016
Braeburn Pharma And Camurus Announce Initiation Of A Phase 2 Study In Opioid Dependent Patients With Moderate To Severe Chronic Pain 2/22/2016
OBI Pharma (SHPG) Reports Topline Results From OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial In Patients With Metastatic Breast Cancer 2/22/2016
Endo International (ENDP) Announces Initiation Of Phase 2B Clinical Trial Of Collagenase Clostridium Histolyticum In Cellulite 2/17/2016
Galapagos (GLPG.BR) Starts SAPHIRA Phase II Study With GLPG1837 In Cystic Fibrosis Patients 2/17/2016
BioInvent (BOVNF) Financial Statement 1 January – 31 December 2015 2/17/2016
Dilaforette Signs Collaboration Agreement With Arabian Gulf University (Bahrain) For Phase 2 Clinical Development Of Sevuparin For Sickle Cell Disease 2/16/2016
DelMar Pharma Announces Second Quarter Fiscal Year 2016 Financial Results And Corporate Update 2/16/2016
e-Therapeutics Sees Mixed Data in Major Depression Drug Trial 2/15/2016
Zealand Pharma  (ZEAL.CO) Doses The First Patients With ZP1848 For Short Bowel Syndrome, Advancing The Second Of Its Proprietary Specialty Medicines Into Phase II Development In 2016 2/15/2016
Aurinia (ISA.TO) To Host Conference Call & Webcast To Review Results From The AURION Study 2/12/2016
Galmed Pharmaceuticals Announces Retirement Of Chief Medical Officer 2/11/2016
Transition Therapeutics (TTH.TO) Announces Second Quarter Fiscal 2016 Financial Results 2/10/2016
Axovant (AXON) Announces Launch Of First-In-Class Clinical Programs For Lewy Body Dementia And Reports Financial Results For The Third Fiscal Quarter Ended December 31, 2015 2/10/2016
ERYtech Pharma Announces 2016 Financial Calendar 2/8/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
Takeda (TKPYY) Release: FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) 2/4/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
Transition Therapeutics (TTH.TO) Announces Top Line Phase 2 Clinical Study Results Of Diabetes Drug Candidate TT401 2/1/2016
BioLineRx Ltd. To Present At 2016 BIO CEO & Investor Conference In New York On February 8 2/1/2016
Medivir (MVRBF) Initiates Phase IIa Study Of MIV-711 In Knee Osteoarthritis 1/28/2016
Genticel's HPV Candidate Did Not Meet Primary Endpoint in Phase II Study 1/27/2016
Galapagos (GLPG.BR) Shuts Down Ulcerative Colitis Program After Drug Failed to Prove Efficacy in Trial 1/26/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
ViroMed Publishes Results From Critical Limb Ischemia (CLI) Phase II Clinical Study 1/22/2016
Summit Therapeutics Receives Regulatory Approval To Initiate Phaseout DMD, A Phase II Clinical Trial Of SMT C1100 In Patients With DMD 1/21/2016
OncoGenex (OGXI) Sinks as Lung Cancer Drug Apatorsem Flunks Phase II Study 1/21/2016
BrainStorm Cell's Stem Cell Treatment Stops Disease Progression in 87% of ALS Patients in Phase II Study 1/12/2016
BrainStorm Cell To Conduct Phase 2 Multi-Dose Nurown Trial In ALS At Hadassah Medical Center 1/11/2016
Roche (RHHBY) Encouraged by Mid-Stage Atezolizumab Bladder Cancer Data 1/8/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
Jubilant Biosys And Sanofi Deutschland Gmbh Enter Into A Strategic Alliance Focusing On Metabolic Disorders Therapeutic Area 1/7/2016
DS Biopharma Announces Positive Top-Line Phase Ila Trial Results For DS107 As An Oral Treatment For Moderate To Severe Atopic Dermatitis 1/7/2016
Vtesse, Inc. Announces FDA's Granting Of Breakthrough Therapy Designation For VTS-270 In Niemann-Pick Type C1 Disease 1/6/2016
ERYtech Pharma Announces Third DSMB Safety Review And Continuation Of Its Phase IIb Study In Acute Myeloid Leukemia 1/6/2016
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016
Galmed Pharmaceuticals To Present At The Biotech Showcase 1/5/2016
BioLineRx Ltd. To Present At Biotech Showcase 2016 Conference In San Francisco 1/4/2016
NeuroDerm (NDRM) Announces Start Of Patient Enrollment In Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 12/30/2015
TWi Biotechnology Inc. Reports Positive Interim Results From AC-201 CR Phase 2 Proof-Of-Concept Study In Gout Patients 12/28/2015
TRANSGENE (ENX:TNG) Announces Publication In "The Lancet Oncology" Of Phase 2b TIME Trial Results With TG4010 Immunotherapy In Non-Small Cell Lung Cancer 12/23/2015
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015
Hemostemix Poised To Expand Phase-2 Clinical Trial Of Lead Product ACP-01 To The United States 12/22/2015
ExCellThera Announces Initiation Of Clinical Trial For Cancer Patients 12/21/2015
Can-Fite BioPharma (CFBI)'s CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma 12/17/2015
OphthaliX Inc. Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma 12/17/2015
Addex Therapeutics (ADXN.SW) Reports Statistically Significant Positive Interim Data For Dipraglurant In Healthy Volunteer mGlu5 Receptor Occupancy Trial 12/17/2015
Yisheng Biopharma And The United States Army Medical Research Institute Of Infectious Diseases Announce Collaboration On New Vaccine Against Ebola Virus 12/14/2015
Poxel Announces Imeglimin Phase 2b Initiation In Japan 12/14/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
Novartis AG (NVS)’s Experimental Therapy Wipes Out Blood Cancer in 93 Percent of Patients 12/11/2015
Novartis AG (NVS)'s Copycat Works Just as Well as Amgen (AMGN)'s Neulasta 12/8/2015
Can-Fite BioPharma (CFBI) Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101 12/7/2015
OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101 12/7/2015
New Clinical Data On MorphoSys AG’s Blood Cancer Drug Candidate MOR208 In NHL And CLL Presented At American Society of Hematology Annual Meeting 12/7/2015
Shares Jump as Foamix Pharma (FOMX)'s FDX104 Shows Efficacy in Phase II Study 12/3/2015
Acacia Pharma: Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman 12/3/2015
NovoCure Release: Preliminary Phase 2 Data Demonstrate Tumor Treating Fields Is Safe In Patients With Brain Metastases Originating From Non-Small Cell Lung Cancer 12/2/2015
ProMetic BioSciences, Inc. Confirms PBI-4050's Efficacy In Patients Suffering From Type 2 Diabetes And Metabolic Syndrome 12/1/2015
Galmed Pharmaceuticals Announces FDA Clearance Of IND Of Aramachol For The Treatment Of Patients With HIV-Associated Lipodystrophy And Nonalcoholic Fatty Liver Disease 12/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016 12/1/2015
BrainStorm Cell Awarded Additional $735,000 Non-Dilutive Grant For 2015 From Israel's Office Of The Chief Scientist 11/30/2015
Otic Pharma Appoints Keith A. Katkin As Chairman Of The Board Of Directors 11/30/2015
SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results In Mesothelioma And Acute Myeloid Leukemia (AML) Patients At The Annual International WT1 Conference 11/30/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Nine Months Ended September 30, 2015 11/30/2015
Oramed (ORMP) Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China 11/30/2015
Allergy Therapeutics plc Completion Of Patient Enrolment In PQBirch204 Phase II Study 11/30/2015
ESSA Pharma Announces Enrollment Of First Patient In Phase 1/2 Trial 11/25/2015
iCo Therapeutics Inc. Announces Third Quarter 2015 Financial Results 11/25/2015
BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015 11/25/2015